John Mandrola, MD

John Mandrola, MD discusses early vs delayed AF ablation, a report on a devastating complication of AF ablation, and a potential crosswind for a major therapeutic fashion in electrophysiology. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Early Vs Delayed Ablation - Impact of Early Versus Delayed Atrial Fibrillation Catheter Ablation on Atrial Arrhythmia Recurrences https://doi.org/10.1093/eurheartj/ehad247 - Diagnosis-to-Ablation Time and Recurrence of Atrial Fibrillation Following Catheter Ablation https://www.ahajournals.org/doi/full/10.1161/CIRCEP.119.008128 - Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation https://www.nejm.org/doi/full/10.1056/nejmoa2029980 - Progression of Atrial Fibrillation after Cryoablation or Drug Therapy https://www.nejm.org/doi/full/10.1056/NEJMoa2212540 II Atrial-Esophageal Fistula CT and Surgery Best Diagnose and Manage Esophageal Fistula https://www.medscape.com/viewarticle/990933 - A worldwide survey on incidence, management and prognosis of oesophageal fistula formation following atrial fibrillation catheter ablation: The POTTER-AF study https://doi.org/10.1093/eurheartj/ehad250 - Oesophageal Probe Evaluation in Radiofrequency Ablation of Atrial Fibrillation (OPERA): results from a prospective randomized trial https://doi.org/10.1093/europace/euaa209 - Temperature monitoring and temperature-driven irrigated radiofrequency energy titration do not prevent thermally induced esophageal lesions in pulmonary vein isolation: A randomized study controlled by esophagoscopy before and after catheter ablation https://doi.org/10.1016/j.hrthm.2021.02.003 III High-Power Short-Duration Ablation Short, High-Power Ablation on Par With Standard AF Ablation https://www.medscape.com/viewarticle/972087 - Power-Fast Trial https://clinicaltrials.gov/ct2/show/NCT04153747 You may also like: Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact: news@medscape.net

Carotid stents, the paclitaxel story now closed, inclisiran, DOAC failures, and primary vs secondary prevention are the topics John Mandrola, MD, covers in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Carotid Stenting CMS Proposal Expanded Coverage of Carotid Stenting in CMS Draft Proposal https://www.medscape.com/viewarticle/994315 No Added Benefit From Revascularization in Low-Risk CAS https://www.medscape.com/viewarticle/992524 - Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with Stenting https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=Y&NCAId=311 - Second asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid artery stenting versus carotid endarterectomy https://doi.org/10.1016/S0140-6736(21)01910-3 - SPACE-2 https://journals.sagepub.com/doi/10.1177/1747493019833017 - Rationale, Design, and Implementation of Intensive Risk Factor Treatment in the CREST2 Trial 10.1161/STROKEAHA.120.030730 II. Paclitaxel FDA: No Excess Mortality Risk From Paclitaxel Stents, Balloons for Peripheral Intervention https://www.medscape.com/viewarticle/994253 - FDA Statement https://www.fda.gov/medical-devices/letters-health-care-providers/update-paclitaxel-coated-devices-treat-peripheral-arterial-disease-unlikely-increase-risk-mortality?utm_medium=email&utm_source=govdelivery#_FDA_Actions III. Inclisiran FDA Expands Inclisiran Statin-Adjunct Indication to Include Primary Prevention https://www.medscape.com/viewarticle/994185 - ORION 10-11 Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol https://www.nejm.org/doi/10.1056/NEJMoa1912387 - Effect of inclisiran on lipids in primary prevention: the ORION-11 trial https://doi.org/10.1093/eurheartj/ehac615 - Inclisiran and cardiovascular events: a patient-level analysis of phase III trials https://pubmed.ncbi.nlm.nih.gov/36331326/ IV. DOAC Failure Association of Alternative Anticoagulation Strategies and Outcomes in Patients With Ischemic Stroke While Taking a Direct Oral Anticoagulant https://doi.org/10.1212/WNL.0000000000207422 V. Primary or Secondary Prevention You may also like: Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Nudges, statins, AI, less-is-more in the ICU, myocarditis, exercise as medicine, and December in the hospital are the topics John Mandrola, MD, covers in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Nudges and Statin Prescribing EHR Alerts to Both Doc and Patient May Boost Statin Prescribing https://www.medscape.com/viewarticle/984944 Effect of Nudges to Clinicians, Patients, or Both to Increase Statin Prescribing https://jamanetwork.com/journals/jamacardiology/article-abstract/2798971 Association of the Hospital Readmissions Reduction Program With Mortality Among Medicare Beneficiaries Hospitalized for Heart Failure, Acute Myocardial Infarction, and Pneumonia https://jamanetwork.com/journals/jama/fullarticle/2719307 Lack of Efficacy of a Salience Nudge for Substituting Selection of Lower-Calorie for Higher-Calorie Milk in the Work Place https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4488787/ II. AI and Chest X-Ray Single Chest X-Ray Could Predict 10-Year CVD Risk https://www.medscape.com/viewarticle/984910 III. BOX Trial Shorter Fever Prevention Duration Effective After Cardiac Arrest https://www.medscape.com/viewarticle/984852 Duration of Device-Based Fever Prevention after Cardiac Arrest https://www.nejm.org/doi/10.1056/NEJMoa2212528 Oxygen Targets in Comatose Survivors of Cardiac Arrest https://www.nejm.org/doi/full/10.1056/NEJMoa2208686 Blood-Pressure Targets in Comatose Survivors of Cardiac Arrest https://www.nejm.org/doi/full/10.1056/NEJMoa2208687 Lower or Higher Oxygenation Targets for Acute Hypoxemic Respiratory Failure https://www.nejm.org/doi/full/10.1056/NEJMoa2032510 IV. Myocarditis Mortality Higher in Myocarditis After Virus Than After COVID Vax https://www.medscape.com/viewarticle/985045 Autopsy-based histopathological characterization of myocarditis after anti-SARS-CoV-2-vaccination https://link.springer.com/article/10.1007/s00392-022-02129-5#Tab2 Myopericarditis After COVID-19 mRNA Vaccination Among Adolescents and Young Adults https://jamanetwork.com/journals/jamapediatrics/fullarticle/2798866 Prognosis of Myocarditis Developing After mRNA COVID-19 Vaccination Compared With Viral Myocarditis https://www.jacc.org/doi/full/10.1016/j.jacc.2022.09.049 V. Exercise as Medicine Just 8 Minutes of Exercise a Day Is All You Need https://www.medscape.com/viewarticle/984684 Vigorous physical activity, incident heart disease, and cancer: how little is enough? https://doi.org/10.1093/eurheartj/ehac572 You may also like: Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine   The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net John M Mandrola, MD

This podcast delves into the intriguing topics of plastics and heart disease, MINT trial LTE and Bayes theorem, and Brugada syndrome. The discussion explores the link between plastic particles in carotid plaques and CV events, the implications of test accuracy and prior probabilities in medical diagnostics, and the demographics and findings of Brugada Syndrome patients.

Chat GPT, a relatively unknown therapy for HFpEF, and two fun studies on statins and secondary prevention are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Artificial Intelligence and CHAT GPT Can ChatGPT Replace Diabetes Educators? Perhaps Not Yet https://www.medscape.com/viewarticle/990381 - Potential and Pitfalls of ChatGPT and Natural-Language Artificial Intelligence Models for Diabetes Education https://doi.org/10.2337/dc23-0197 II. Exercise and HFpEF AHA, ACC Advocate Supervised Exercise Training in HFpEF https://www.medscape.com/viewarticle/990351 - Supervised Exercise Training for Chronic Heart Failure With Preserved Ejection Fraction: A Scientific Statement From the American Heart Association and American College of Cardiology https://doi.org/10.1016/j.jacc.2023.02.012 III. Statins and Muscles Statins Don't Worsen Muscle Injury From Moderately Intense Exercise https://www.medscape.com/viewarticle/990473 - Prolonged Moderate-Intensity Exercise Does Not Increase Muscle Injury Markers in Symptomatic or Asymptomatic Statin Users https://doi.org/10.1016/j.jacc.2023.01.043 IV. Statins in Secondary Prevention Treat to LDL Target or High-Intensity Statin for All With Clinical CAD: LODESTAR https://www.medscape.com/viewarticle/989884 - Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease https://jamanetwork.com/journals/jama/article-abstract/2802214 You may also like: Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact: news@medscape.net

Beta-blockers post MI, public perception of statins, trust in the medical profession, BMI, and TAVI are the topics John Mandrola, MD, covers in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Post-MI Beta Blockers Long-term Beta-Blockers Not Needed After MI with Preserved Systolic Function? https://www.medscape.com/viewarticle/991542 - Association of beta-blockers beyond 1 year after myocardial infarction and cardiovascular outcomes https://heart.bmj.com/content/early/2023/04/16/heartjnl-2022-322115 - Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure https://www.nejm.org/doi/full/10.1056/nejmoa1608029 II. Statin Perceptions Statin Misinformation on Social Media Flagged by AI https://www.medscape.com/viewarticle/991585 - Artificial Intelligence–Enabled Analysis of Statin-Related Topics and Sentiments on Social Media https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2803988 III. BMI BMI Is a Flawed Measure of Obesity. What Are Alternatives? https://www.medscape.com/viewarticle/991210 IV. TAVI Access Better Access to Transcatheter Aortic Valve Replacement Associated With Improved Outcomes https://www.medscape.com/viewarticle/991573 - Regional Differences in Outcomes for Patients Undergoing Transcatheter Aortic Valve Replacement in New York State and Ontario https://doi.org/10.1016/j.cjca.2023.01.025 You may also like: Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact: news@medscape.net

John Mandrola, MD, discusses a variety of topics in cardiology, such as an update on Impella, TAVI vs SAVR trial results, studies on angina and PCI, complete revascularization, and Semaglutide research. The podcast covers a range of important advancements and findings in the field of cardiology, providing valuable insights for healthcare professionals.

Cardiologist John Mandrola discusses ICD generator changes, less is more in VT management, comorbidity in HF, and SGLT2i after AF ablation. Topics include patient perspectives on generator exchanges, ischemia testing and monomorphic VT storm, hospital admissions in the last year of life of HF patients, and the impact of SGLT2 inhibitors on AFib recurrence.

Dr. John Mandrola, a cardiologist with a wealth of knowledge, dives into crucial topics like the flawed concept of surgical clearance in cardiology, emphasizing the importance of understanding surgical risks. He critiques current preoperative practices and advocates for advanced imaging over traditional tests. The discussion also explores the underuse of guideline-directed medical therapy in heart failure patients. Additionally, Dr. Mandrola highlights how patient preferences significantly influence treatment decisions, underscoring the need for personalized approaches in cardiology.

John Mandrola, MD, a seasoned cardiologist, and Sripal Bangalore, a cardiac research expert, delve into some urgent issues in cardiology. They discuss the implications of FDA Class I device recalls and the troubling disparities in preventive care access for marginalized patients. The duo also tackles the risks of prematurely stopping clinical trials and the impact of potassium management on post-surgery outcomes. Plus, listeners are updated on the positive results of the SHAM-PVI trial for AF ablation, revealing its intriguing effects.